Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ophtesis Bio is a cohesive ophthalmic viscosurgical device (OVD) composed of 3% sodium hyaluronate, developed by Aptissen. It is primarily indicated for use during cataract surgery to maintain the depth of the anterior chamber and protect intraocular tissues, particularly the corneal endothelium, from mechanical trauma during surgical maneuvers. As a cohesive OVD, it maintains its structure under low shear rates, providing excellent space maintenance, and is designed to be easily aspirated from the eye at the conclusion of the procedure to minimize the risk of postoperative intraocular pressure (IOP) spikes. The product is typically supplied as a sterile, non-pyrogenic, clear solution in a pre-filled syringe.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Ophtesis Bio.